Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stupp joins SAB for Alpheus Medical, a sonodynamic therapy (SDT) platform targeting solid body cancers.
Alpheus SAB Announcement
All should complain to the reporter's boss that owns the paper.
Iliffe Media Ltd
Of course, the main issue is posters saying "it says" means Linda Powers said it. The fact is, it is NWBio "saying 'it' ". The companies press releases say it new the bottom, since 2020.
I can't find flippers reference to powerscout, so, not sure if that is good or bad info.
Powerscourt?? Who is that?
41K holders, StockTwits has 10K followers..Odd.
We must have picked up some meme chasers in their basements. LOL.
Well, some records burned up a few weeks ago. lol.
FeMike, yes, like the bag thing, my concern is the appearance of collusion when posters have been clarified, but still state the mis-information.
It happened the other day on who owns Advent Bio.
GoodGuyBill Please read this post.
GoodGuyBill, please read this.
Rest Easy 10baggerz, last ASM was May 18, you have some time to manifest a price drop... or de-invest, then no more to worry about.
Exactly my point on this dead horse... the promotion machine indicates LPOW said these words, live, for the first time, in a Cambridge Independent article. The fact is, they are recycled words from the "about NW bio" placed at the bottome of every PR they have made since data lock.
nothing wrong with articles or NWBO doing this... it's how it is played by others later that bugs me.
Actual article read is helpful '"The Maryland-based biotechnology company has been developing DCVax personalised immune therapies for solid tumour cancers, with input from its R&D team at Sawston. These therapies, it says, “treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe”.'
Notice "it says", right after mentioning R&D team at Sawston... quote NOT attributed to Ms. Powers... only "it says"...
few paragraphs later, 'Ms Powers said: “We are very pleased to be commencing production at Sawston for compassionate use.
“It will result in a significant expansion of production capacity for our dendritic cell cancer vaccine for compassionate use and follows the December approval by the MHRA for the manufacture of GMP (clinical grade) cell therapy products for such use.
“That Northwest Biotherapeutics, together with our contractor Advent BioServices, have been able to achieve this milestone during a global pandemic is testament to the persistence, dedication and expertise of our highly skilled teams.”
“We look forward to continued progress at Sawston in the coming months as we focus on the next phase of the build-out,” concluded Ms Powers.
Cambridge Independant Article 02/25/2022
Standard Statement on PR's since Data Lock 10/2020
Data Lock PR 10/2020
the section "About Northwest Biotherapeutics" is on all of them since then. Nothing to get pumped up about.
"About Northwest Biotherapeutics"
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial, and is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
And I copy/pasted what you copy/pasted... which, is what the article writer's do. Some out there raise it up to be a golden chalice to promote the stock. When it is often old or recycled statements... accurate, but recycled words.
I want something NEW...that is about NWBO and not Tucan's Advent Bio.
A tad Mis-leading from DI .. or poster
The phrase "treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe” Attributed to recent LPOW UK interviews, well... see nwbio.com press release "about Northwest Biotherapeutics"
You will see this... (I only went back to 05/12/2021 PR)
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial is now completed, with the trial data now being analyzed. The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
I thought Advent got the license? This part is still gray-area for me.
Construction in Progress
In connection with the Company’s manufacturing facility in U.K, the Company has incurred and is incurring costs with certain vendors to design and build out certain stages of the facility. Additionally, the Company purchased certain manufacturing equipment that has been or will be installed in connection with the buildout. These costs were all capitalized and recorded as part of construction in progress at December 31, 2020. The Company received approval of a license for collection and processing of human cells and tissues, and a license for manufacture of cell therapy products for compassionate use at its Sawston, UK facility in December 2021. All costs associated with the facility buildout were reclassified from construction in progress to leasehold improvements effective December 2021 as a result of the receipt of the MHRA license and amortized over the estimated useful life of the facility.
Not "New" Lancet story..
It's great to hear continued talking about PFS vs. OS... I mean, I would rather be alive, than not have been given a treatment because it might progress..
Just don't get Yedi Mind-tricked in to thinking this "must be becasue of DCvax..." Pipe Dream.
Company clearly wanting Combo approval before P3 results.
2012 PFS from Same Author
Bio, eagle8 Flat Out Said it..
Posting 446818
"NWBO owns Advent.
Only the staff are hired NWBO staff.
GLTU"
How come negative nellies have not rotated conversation to LPOW in a while?? Seems like they are gearing up to do that today or Monday.
It's kind of a wash, rinse, repeat cycle I have noticed.
The Tucan owned Advent has been discussed to death here. Proven and not questioned. Anyone saying NWBO owns Advent is lying.
Wow, that is Teamwork way too obvious.
Dang It LC, I agree...
I was actually Shocked and Awed to see her quoted.... I had too read it twice, ok, three times.
I do however believe the specific language about "compassionate use" could protect ''the' quiet period'(lol) and not ruffle feathers of any posters regarding FDA advertising. Plus, no mention of Ph3 trial. So, that is protected.
She's crafty, wordsmithy, and I personally, am on her side. But I respect those who have chosen Darth Vader.
Maverick408 Nice Find/Update on Advent Bio UK..
Dare I say 'one more breadcrumb'... lol...
Current Share Count. Bookmark the Link
NWBO Security Info
I think Bigger was in Bethesda for a company called Alset EHome International Inc.
Just as plausible.
I know it's "old news", but it popped up "again" on Twitter this morning and yesterday on IHUB.
No. Simply announcing a location change of an existing activity does not seem to end a quiet time period. IMHO. The ability for Sawston to produce is HUGE. As Hannibal Smith says... "I love it when a plan comes together"
It's like a Indy car race, it only matters who gets the checkered flag.
The action throughout the race is forgotten.
It could be great passing, a bad crash, new technology being race proven.
I personally try to ignore the price changes/attacks, knowing I am in it to win it, not the "us versus them" mentality.
Pattyloco, it's all about P3 and Combo data. Reality is, the UK, right now, is "compassionate use" a.k.a. "special"... so, in one way, that's not new news... but, to do it in a 100% Brand Spanking New Facility, Oh Yeah... WOW!!!!
I get goose bumps being so proud of the Advent Bio team. (which is not owned by NWBO)
Now, if we can get NICE to approve...well... that would be good.
BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.
This milestone follows approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility for compassionate use cases, and approval by the Human Tissue Authority (HTA) of a license for collection and processing of human cells and tissues for medical purposes. Under this regulatory program in the UK, the vaccine is identified as ADCV ("Autologous Dendritic Cell Vaccine").
As previously reported, the MHRA license was received in December of 2021, following nearly two years of preparations. This included hiring and training of technical staff, preparation of approximately 1,000 regulatory documents (including Standard Operating Procedure documents and others), validation of facilities, equipment and protocols, and practice manufacturing cycles. This was followed by a review and detailed inspection by the MHRA.
Since the issuance of the MHRA license, Advent Bioservices, NW Bio's contract manufacturer in the UK, has been conducting the required post-approval re-validations and testing so that the facility is now ready for the manufacture of cell therapy products for clinical use. Accordingly, the first vaccine production for compassionate use treatment for a glioblastoma patient has now begun in the Sawston facility.
The Company anticipates that Phase 1A of the Sawston facility will have the capacity to produce cancer vaccines for 450-500 patients per year. The Company plans to continue developing the Sawston facility in phases, both to calibrate the capital expenditures with the capacity needed and to leave room for implementation of new technologies such as the Flaskworks system.
AHHWWW YEEAHHHHH....
Nice Press Release.
AEK, Go For It, you have a Keyboard and Ears!! Thank you in advance for the transcript.
I think the paper trail was too bad for them... the Adam thing, knowwhatyoouhold posting negative posts roughly the same time... not very smooth planning. IMHO.
To someone who says knowwhatyouhold was hacked... then why would they leave the "long Due Dilligence(DD)" posts unharmed. Does not pass the smell test.
The negative posts have been removed by the way.
OK, I see the event, but what was said... ????
That will be interesting to find out.
BIO CEO investors conference
I don't like the guy either, but I know what he is about, so, it lessens the impact for me.
But it also means he is scouring the internet for any tid-bit of negative info he can, knowing what might be headed his way.
Perhaps he just wants more cheap shares... I DO TOO... lol.
Yes, he also said "we consider ourselves third generation". So, grain of salt, being an investors presentation basically.
I'm expecting a bear raid will still happen tomorrow however.
Technically, AF has done nothing wrong, going back to the bank vault of out dated info.
Look how many posters breadcrumb old positive info... he was probably watching a presentation and those presenters called NWBO a failure. So, true to what he tweeted.
He is simply breadcrumbing a failure narrative.
FOUND IT !! Aivita April 2021
Aivita April 2021
Spellcheck error, AF's Aivita biomedical is not Avita Medical that is at BTIG(like I thought)... SO, I don't know if AF is watching something new or Old ?? He could be making a true statement, but the private presentation or video could be 5 year old for all we know, but still be a true stament that he is watching it... wordsmith perhaps.
We need to find source of Aivita presentaion, but being a private company, who knows.
BTIG Medtech conf today. Question is if we are considered second generation or east that for non-gbm?
BTIG event maybe? Scrambling here...
We know the Origin of the F-word... and oh boy, I am penetrating that field with the entire weight of my Roth IRA...no 10% to the big guy.